

AT A REGULAR MEETING OF THE GLOUCESTER COUNTY BOARD OF SUPERVISORS, HELD ON TUESDAY, SEPTEMBER 2, 2025, AT 6:00 P.M., IN THE COLONIAL COURTHOUSE AT 6504 MAIN STREET, GLOUCESTER, VIRGINIA ON A MOTION MADE BY _____, AND SECONDED BY _____, THE FOLLOWING RESOLUTION WAS ADOPTED BY THE FOLLOWING VOTE:

Phillip N. Bazzani, ____;
Ashley C. Chriscoe, ____;
Kenneth W. Gibson, ____;
Christopher A. Hutson, ____;
Michael A. Nicosia, ____;
Robert J. Orth, ____;
Kevin M. Smith, ____;

**A RESOLUTION OF THE GLOUCESTER COUNTY BOARD OF SUPERVISORS
APPROVING OF THE COUNTY’S PARTICIPATION IN THE PROPOSED
SETTLEMENT OF OPIOID-RELATED CLAIMS AGAINST ALVOGEN,
AMNEAL, APOTEX, HIKMA, INDIVIOR, MYLAN, SUN, AND ZYDUS, AND
DIRECTING THE COUNTY ATTORNEY TO EXECUTE THE DOCUMENTS
NECESSARY TO EFFECTUATE THE COUNTY’S PARTICIPATION IN THE
SETTLEMENTS**

WHEREAS, the opioid epidemic that has cost thousands of human lives across the country also impacts the Commonwealth of Virginia and its counties and cities, including the County of Gloucester, by adversely impacting the delivery of emergency medical, law enforcement, criminal justice, mental health and substance abuse services, and other services by Gloucester County’s various departments and agencies; and

WHEREAS, the Commonwealth of Virginia and its counties and cities, including Gloucester County, have been required and will continue to be required to allocate substantial taxpayer dollars, resources, staff energy and time to address the damage the opioid epidemic has caused and continues to cause the citizens of the Commonwealth and Gloucester County; and

WHEREAS, settlement proposals have been negotiated that will cause the opioid manufacturers Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus (collectively, “the Manufacturers”) to pay an aggregate of approximately \$720 million dollars nationwide to resolve opioid-related claims against them; and

WHEREAS, Gloucester County has approved and adopted the Virginia Opioid Abatement Fund and Settlement Allocation Memorandum of Understanding (the “Virginia MOU”), and affirms that each of the pending

settlements with the Manufacturers shall be considered a “Settlement” that is subject to the Virginia MOU, and shall be administered and allocated in the same manner as the opioid settlements entered into previously with opioid distributors McKesson, Cardinal Health, and AmerisourceBergen, opioid manufacturers Janssen Pharmaceuticals, Teva Pharmaceuticals, and Allergan, and retail pharmacy chains CVS, Walgreens, Walmart, and Kroger; and

WHEREAS, the County Attorney has reviewed the available information about the proposed settlements with the Manufacturers and has advised that the County’s participation in the settlements would be lawful, and that participation is required in order for the County to receive its share of the funds that the settlements would provide;

NOW THEREFORE BE IT RESOLVED that the Gloucester County Board of Supervisors, this 2nd day of September, 2025, approves of the County’s participation in the proposed settlements of opioid-related claims against the Manufacturers, and directs the County Attorney to execute the documents necessary to effectuate the County’s participation in the settlements, including the required release of claims against the Manufacturers.

A Copy Teste:

Carol E. Steele, County Administrator

Bohannon, Cynthia P.

From: Beshere, Thomas M. <TBeshere@oag.state.va.us>
Sent: Thursday, August 21, 2025 3:23 PM
To: Beshere, Thomas M.
Subject: IMPORTANT -- PLEASE READ -- Multistate opioid settlement with eight opioid manufacturers -- Approval and sign-on process -- OCTOBER 8, 2025 DEADLINE
Attachments: national_opioid_settlement_notice_settlement_overview.pdf; DRAFT RESOLUTION (August 2025) for non-litigating cities and counties - Approval of Settlements with Eight Opioid Manufacturers.docx

CAUTION: This email originated from a source outside of Gloucester County. Avoid clicking on links or attachments unless you are sure of the sender and know that the content is safe.

Counsel and Administrators:

On behalf of the Office of the Attorney General of Virginia, I am writing to provide information to you about multistate opioid settlements that have been reached with eight opioid manufacturers: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. By now, you should have received an initial notice about these settlements from Rubris, the settlement implementation administrator. A copy of that initial notice is attached for your reference. (If you did not receive this notice, please let me know and I will contact Rubris to make sure they have the correct contact information for your locality.)

You will soon be receiving (if you have not already received) another notification from Rubris, accompanied by a sign-on form that you will need to complete and submit to join and participate in these settlements. The notice from Rubris will include instructions on how to complete and submit the form.

In the meantime, I am attaching a draft resolution for your board or council to approve your locality's participation in the settlements, and to authorize a responsible official to complete, sign, and submit the participation form.

Once again, the amount of funds that will flow to Virginia and its localities from these settlements depends on maximizing participation by as many local government subdivisions as possible. We achieved 100% participation in the previous multistate opioid settlements with opioid distributors McKesson, Cardinal Health, and AmerisourceBergen, opioid manufacturers Johnson & Johnson, Teva, and Allergan, and retail pharmacy chains CVS, Walgreens, Walmart, and Kroger. We would like to achieve the same 100% participation rate for these settlements settlement as well. As in our prior multistate opioid settlements, all Virginia counties and independent cities are eligible to receive a direct share of settlement funds pursuant to the allocation methodology in the Virginia Opioid Abatement Fund and Settlement Allocation Memorandum of Understanding ("MOU") and the Virginia Opioid Abatement Act. However, any eligible locality that wishes to receive settlement funds must confirm its participation by completing and submitting the participation form. Localities that do not submit a participation form will not be eligible to receive any distributions from the settlement.

The deadline for submitting your participation forms is **October 8, 2025**, so please put the resolution on the agenda for your next board meeting, then complete and submit the participation forms as soon as possible.

As always, please feel free to contact me if you have any questions.

Thank you,
Tom Beshere

Thomas M. Beshere
Senior Assistant Attorney General
Office of the Attorney General
202 North 9th Street
Richmond, Virginia 23219
(804) 823-6335 Office
TBeshere@oag.state.va.us
<http://www.ag.virginia.gov>



Thomas M. Beshere | Senior Assistant Attorney General
Office of the Attorney General
202 North 9th Street
Richmond, Virginia 23219
O: (804) 823-6335 | M: | F:
TBeshere@oag.state.va.us
<https://www.oag.state.va.us>

National Opioids Settlements: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, Zydus
Opioids Implementation Administrator
opioidsparticipation@rubris.com

Gloucester County, VA
Rubris Reference Number: CL-1769121

***TO LOCAL POLITICAL SUBDIVISIONS AND SPECIAL DISTRICTS:
THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT NATIONAL OPIOID
SETTLEMENTS.***

SETTLEMENT OVERVIEW

Proposed nationwide settlement agreements ("Settlements") have been reached that would resolve opioid litigation brought by states, local political subdivisions, and special districts against eight opioids manufacturers, Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus (the "Manufacturers"). Local political subdivisions and special districts are referred to as "subdivisions."

The Settlements require the settling Manufacturers to pay hundreds of millions of dollars to abate the opioid epidemic. The Settlements will provide a maximum of approximately \$720 million in cash to participating states and subdivisions to remediate and abate the impacts of the opioid crisis. Depending on participation by states and subdivisions, the Settlements require:

- Alvogen to immediately pay up to approximately \$19 million;
- Amneal to pay up to approximately \$74 million over 10 years, and to provide either approximately \$177 million of its generic version of the drug Narcan or up to an additional approximately \$44 million in cash;
- Apotex to immediately pay up to approximately \$65 million;
- Hikma to immediately pay up to approximately \$98 million, and to provide either approximately \$35 million of its naloxone product or up to an additional approximately \$7 million in cash;
- Indivior to pay up to approximately \$75 million over five years, a portion of which, at the election of the state, could be paid in the form of Indivior's branded buprenorphine and/or nalmefene products with a value of up to \$140 million.;
- Mylan to pay up to approximately \$290 million over nine years;
- Sun to immediately pay up to approximately \$32 million; and
- Zydus to immediately pay up to approximately \$15 million.

The Settlements also contain injunctive relief governing opioid marketing, sale, distribution, and/or distribution practices and require the Manufacturers to implement safeguards to prevent diversion of prescription opioids.

Each of the proposed settlements has two key participation steps.

First, each eligible state decides whether to participate in each Settlement. A list of participating states for each settlement can be found at <https://nationalopioidsettlement.com/>.

Second, eligible subdivisions within each participating state decide whether to participate in each Settlement. The more subdivisions that participate, the more funds flow to that state and its subdivisions. Any subdivision that does not participate cannot directly share in any of the settlement funds, even if the subdivision's state is settling and other participating subdivisions are sharing in settlement funds. If the state does not participate in a particular Settlement, the subdivisions in that state are not eligible to participate in that Settlement.

WHO IS RUBRIS INC. AND WHAT IS THE IMPLEMENTATION ADMINISTRATOR?

The Settlements provide that an Implementation Administrator will provide notice and manage the collection of participation forms. Rubris Inc. is the Implementation Administrator for these new Settlements and was also retained for the prior national opioid settlements.

WHY IS YOUR SUBDIVISION RECEIVING THIS NOTICE?

Your state has elected to participate in one or more of the Settlements, and your subdivision may participate in those Settlements in which your state has elected to participate. This notice is also sent directly to counsel for such subdivisions if the Implementation Administrator has their information.

If you are represented by an attorney with respect to opioid claims, please contact them.

Subdivisions can participate in the Settlements whether or not they filed a lawsuit or are represented.

WHERE CAN YOU FIND MORE INFORMATION?

Detailed information about the Settlements, including each settlement agreement, may be found at: <https://nationalopioidsettlement.com>. This website also includes information about how the Settlements are being implemented in most states and how funds will be allocated within your state.

You are encouraged to review the settlement agreement terms and discuss the terms and benefits with your counsel, your Attorney General's Office, and other contacts within your state. Information and documents regarding the Settlements and your state allocation can be found on the settlement website at <https://nationalopioidsettlement.com/>.

Your subdivision will need to decide whether to participate in the proposed Settlements, and subdivisions are encouraged to work through this process before the **October 8, 2025** deadline.

HOW DO YOU PARTICIPATE IN THE SETTLEMENTS?

The Settlements require that you take affirmative steps to "opt in" to the Settlements.

In the next few weeks, you will receive documentation and instructions from the Implementation Administrator or, in some cases, your Attorney General's Office. In order to participate in a settlement, a subdivision must sign and return the required Participation Form for that settlement.

Please add the following email addresses to your "safe" list so emails do not go to spam / junk folders: dse_na3@docusign.net and opioidsparticipation@rubris.com. Please monitor your email for the Participation Forms and instructions.

All required documentation must be signed and returned on or before **October 8, 2025**.

7400 Justice Drive, P. O. Box 1309
Gloucester, VA 23061
(804) 693-5575 phone
(804) 693-2530 fax

From: National Opioid Settlements Implementation Administrator <opioidsparticipation@rubris.com>
Sent: Tuesday, July 15, 2025 12:18 PM
To: Wilmot, Edwin (Ted) <ewilmot@gloucesterva.info>
Cc: Bohannon, Cynthia P. <cbohannon@gloucesterva.info>
Subject: NEW NATIONAL OPIOID SETTLEMENT NOTICE - Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, Zydus - RefNum CL-1769121

CAUTION: This email originated from a source outside of Gloucester County. Avoid clicking on links or attachments unless you are sure of the sender and know that the content is safe.

To: Gloucester County, VA
Rubris Reference Number: CL-1769121

**NOTICE OF NEW NATIONAL OPIOID SETTLEMENTS
AND UPCOMING ACTION NEEDED TO PARTICIPATE**

New national opioid settlements have been reached with Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. This is the formal notice required by the settlements and authorized by the parties.

Please read this email and the attached document carefully.

You are receiving this notice because your State has elected to participate in one or more of the eight national opioid settlements with **Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus**. The list of participating states for each settlement can be found at <https://nationalopioidsettlement.com>. Your subdivision or special district may participate in each settlement for which your State has elected to participate.

Your subdivision or special district might have participated in prior national opioid settlements, including those with Johnson & Johnson/Janssen, Cardinal, AmerisourceBergen, McKesson, Teva, Allergan, CVS, Walgreens, Walmart, or Kroger. This notice concerns the opportunity to participate in one or more of the **new** settlements with eight **new** Settling Defendants (**Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus**). Your subdivision or special district may participate in a new settlement even if it did not participate in a prior national settlement. In the next few weeks, you will receive additional information and documentation to sign and return if you wish to join the new settlements. Please review the list of individuals on this email and contact the Opioids Implementation Administrator at opioidsparticipation@rubris.com if someone else at your subdivision or special district should receive communications about these settlements.

Your subdivision or special district must "opt in" to participate in the new settlements. To do so, you must sign and return the documentation that you will be receiving in the next few weeks.

This notice is different than the notice you recently received from Rubris concerning a settlement with Purdue Pharma, L.P, and the Sackler Family. The settlements discussed in this notice are different than the settlement with Purdue and the Sacklers, and you may participate in the settlements discussed in this notice regardless of whether you join the Purdue and Sackler settlement.

The deadline to return the required documentation is October 8, 2025.

Documentation submitted for prior national settlements is not applicable to the new settlements.

The attached document provides additional information concerning the new national opioids settlements involving **Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus**.

Questions about this notice or the process for receiving and submitting the required Settlement Participation Forms may be directed to your attorney, the Opioids Implementation Administrator at opioidsparticipation@rubris.com, or your Attorney General's Office.

If your subdivision or special district is represented by an attorney with respect to opioid claims and they are not copied on this message, please immediately contact them concerning this notice.

Thank you,

National Opioids Settlements Implementation Administrator

National Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus Settlements

The Implementation Administrator is retained to provide the settlement notice required by the respective settlement agreements referenced above and to manage the collection of settlement participation forms for each settlement.

NOTICE: Email messages from Gloucester County are intended solely for the use of those to whom they are addressed and may contain confidential or legally privileged information. While all reasonable precautions have been taken to ensure that emails are virus-free, Gloucester County is not responsible for any damages from viruses or corrupted contents of emails and suggests that you subject these to your virus checking procedures prior to use. If you have received this message in error, please notify the sender and delete or destroy all copies.